Fig. 2

Therapeutic effect of hMSC-derived secretion product on cerebral ischemic via intranasal approach. A: TTC staining illustrating infarct volume post stroke. B: Statistical analysis of infarct volume treated with different concentrations of hMSC-L. C: Neurological function scores for mice treated with different concentrations of hMSC-L. D: Statistical analysis of infarct volume treated with different concentrations of hMSC-M. E: Neurological function scores for mice treated with different concentrations of hMSC-M. F: Representative images and damaged cells statistical analysis (J) of HE stained sections of the cerebral cortex following treatment with hMSC-L(× 200). G: Representative images and damaged cells statistical analysis (L) of HE stained sections of the cerebral cortex following treatment with hMSC-M (× 200). H: Representative images and statistical analysis (K) of Nissl body in the cortex following treatment with hMSC-L (× 200). I: Representative images and statistical analysis (M) of Nissl body in the cortex following treatment with hMSC-M (× 200). n = 5 or 10; versus MCAO ^**P < 0.01, ^***P < 0.001; 1 mg/mL vs 2 mg/mL ns: no significance; ^#P < 0.05, ^##P < 0.01, ^###P < 0.001